These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24554646)

  • 1. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
    Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
    Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
    Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
    Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
    Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
    PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
    Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.
    Muto C; Shoji S; Tomono Y; Liu P
    Antimicrob Agents Chemother; 2015; 59(6):3216-23. PubMed ID: 25801557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
    Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
    Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
    Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
    Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
    Hicks JK; Crews KR; Flynn P; Haidar CE; Daniels CC; Yang W; Panetta JC; Pei D; Scott JR; Molinelli AR; Broeckel U; Bhojwani D; Evans WE; Relling MV
    Pharmacogenomics; 2014 Jun; 15(8):1065-78. PubMed ID: 25084200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.
    Liu L; Zhou X; Wu T; Jiang H; Yang S; Zhang Y
    Int J Antimicrob Agents; 2017 Apr; 49(4):483-487. PubMed ID: 28159657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
    Zhong X; Tong X; Ju Y; Du X; Li Y
    Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
    Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
    J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.